|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/70 | |
| A61K 31/4535 | |||
| A61K 31/5517 | |||
| A61K 9/00 | |||
| A61P 25/20 |
| (11) | Number of the document | 2604257 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13158781.8 |
| Date of filing the European patent application | 2008-08-07 | |
| (97) | Date of publication of the European application | 2013-06-19 |
| (45) | Date of publication and mention of the grant of the patent | 2017-06-28 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 954501 P | 2007-08-07 | US |
| (72) |
Palmer, Pamela, US
Tzannis, Stelios, US
Schreck, Thomas, US
|
| (73) |
Acelrx Pharmaceuticals, Inc.,
575 Chesapeake Drive, Redwood City, CA 94063,
US
|
| (54) | Oral transmucosal dosage forms comprising sufentanil and triazolam |
| Oral transmucosal dosage forms comprising sufentanil and triazolam |